Laminin protein therapy for the treatment of Laminin-alpha2 deficient congenital muscular dystrophy
Description preview
Project Summary
Laminin-α2-related Congenital Muscular Dystrophy (LAMA2-CMD), also known as Merosin Deficient
Congenital Muscular Dystrophy type 1A (MDC1A), is a devastating neuromuscular disease characterized by
progressive muscle weakness from birth. LAMA2-CMD is caused by mutations in the LAMA2 gene, which results
in the loss of the Laminin-α2…
Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click